CA2177392A1 - Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family - Google Patents

Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family

Info

Publication number
CA2177392A1
CA2177392A1 CA002177392A CA2177392A CA2177392A1 CA 2177392 A1 CA2177392 A1 CA 2177392A1 CA 002177392 A CA002177392 A CA 002177392A CA 2177392 A CA2177392 A CA 2177392A CA 2177392 A1 CA2177392 A1 CA 2177392A1
Authority
CA
Canada
Prior art keywords
carbon
epidermal growth
growth factor
factor receptor
tyrosine kinases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002177392A
Other languages
French (fr)
Other versions
CA2177392C (en
Inventor
Alexander James Bridges
William Alexander Denny
David Fry
Alan Kraker
Howard Daniel Hollis Showalter
Robert Frederick Meyer
Gordon William Rewcastle
Andrew Mark Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Alexander James Bridges
William Alexander Denny
David Fry
Alan Kraker
Howard Daniel Hollis Showalter
Robert Frederick Meyer
Gordon William Rewcastle
Andrew Mark Thompson
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/358,352 external-priority patent/US5679683A/en
Application filed by Alexander James Bridges, William Alexander Denny, David Fry, Alan Kraker, Howard Daniel Hollis Showalter, Robert Frederick Meyer, Gordon William Rewcastle, Andrew Mark Thompson, Warner-Lambert Company filed Critical Alexander James Bridges
Priority claimed from PCT/US1995/000911 external-priority patent/WO1995019970A1/en
Publication of CA2177392A1 publication Critical patent/CA2177392A1/en
Application granted granted Critical
Publication of CA2177392C publication Critical patent/CA2177392C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Epidermal growth-factor inhibitors of formula (I), wherein: 1) Y and Z are both C (carbon), both N or one N and the other C, in which case the ring structure is a linearly fused 6,6 (5 or 6) tricycle, or 2) one of Y and Z is C=C, C=N, whereupon the other one of Y or Z is simply a bond between the two aromatic rings, then the ring structure is a nonlinear 6,6 (5 or 6) tricycle, or 3) one of Y and Z is N, O or S, whereupon the other one of Y or Z is simply a bond between the two aromatic rings, then the ring structure is a fused 6,5 (5 or 6) tricycle; A, B, D and E can all be carbon, or up to two of them can be nitrogen, whereupon the remaining atoms must be carbon, or any two contiguous positions in A-E can be a single heteroatom, N, O or S, forming a five membered fused ring, in which case one of the two remaining atoms must be carbon, and the other can be either carbon or nitrogen. X = O, S, NH or NR9, such that R9 = lower alkyl, OH, NH2, lower alkoxy or lower monoalkylamino m =
0-3, and Ar is phenyl, thienyl, furanyl, pyrrolyl, pyridyl, pyrimidyl, imidazolyl, pyrazinyl, oxazolyl, thiazolyl, naphthyl, benzothienyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl and quinazolinyl.
CA002177392A 1994-01-25 1995-01-23 Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family Expired - Fee Related CA2177392C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US18673594A 1994-01-25 1994-01-25
US18674594A 1994-01-25 1994-01-25
US186,735 1994-01-25
US186,745 1994-01-25
US08/358,352 US5679683A (en) 1994-01-25 1994-12-23 Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US358,352 1994-12-23
PCT/US1995/000911 WO1995019970A1 (en) 1994-01-25 1995-01-23 Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family

Publications (2)

Publication Number Publication Date
CA2177392A1 true CA2177392A1 (en) 1995-07-27
CA2177392C CA2177392C (en) 2006-06-20

Family

ID=37392500

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002177392A Expired - Fee Related CA2177392C (en) 1994-01-25 1995-01-23 Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family

Country Status (1)

Country Link
CA (1) CA2177392C (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112778333A (en) * 2021-01-23 2021-05-11 中国科学院新疆理化技术研究所 Tetrahydrooxazolopyridino-azoxanone derivative and application thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112778333A (en) * 2021-01-23 2021-05-11 中国科学院新疆理化技术研究所 Tetrahydrooxazolopyridino-azoxanone derivative and application thereof
CN112778333B (en) * 2021-01-23 2022-07-05 中国科学院新疆理化技术研究所 Tetrahydrooxazolopyridino-azoxanone derivative and application thereof

Also Published As

Publication number Publication date
CA2177392C (en) 2006-06-20

Similar Documents

Publication Publication Date Title
MX9602109A (en) Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family.
BG104598A (en) Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas
IL157773A0 (en) 2-amino-propanol derivatives
HUP0103617A2 (en) Pyrrole substituted 2-indolinone protein kinase inhibitors, pharmaceutical compositions containing the compounds and their use
CA2094773A1 (en) 2,4-dioxoimidazolidine derivatives
RS20050915A (en) Substituted indazolyl(indolyl) maleimide derivatives as kinase inhibitors
CA2047773A1 (en) Derivatives of benzofuran, benzothiophene, indole and indolizine, process for their preparation as well as the compositions containing them
WO1997025321A3 (en) Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
CA2241787A1 (en) Substituted aza- and diazacycloheptane and cyclooctane compounds and their use
EP0358190A3 (en) Polysiloxanes with sterically hindered moiety
WO2003035615A3 (en) Tyrosine kinase inhibitors
CA2130837A1 (en) Fuel additive compositions containing aliphatic amines and polyalkyl hydroxyaromatics
CA2155843A1 (en) Novel urea derivatives, their preparation and use
WO2003035616A3 (en) Tyrosine kinase inhibitors
WO2003035614A3 (en) Tyrosine kinase inhibitors
CA2177392A1 (en) Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
AU8176194A (en) Alkoxymethylation of pyrroles
CA2014490A1 (en) Diaminoethylene compounds
MY108185A (en) Neuroleptic perhydro-1h-pyrido (1,2-a) pyrazines
ES2152379T3 (en) CONDENSED DIHYDROPIRIDINS AND ITS USE FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS.
AP9400638A0 (en) Water soluble derivatives of camptothecin.
WO2001010863A3 (en) Substituted thienyl(amino)sulfonylureas
ATE206755T1 (en) USES OF A PROTEIN KINASE OF CLAY AND NEUROFILAMENT PK40
WO2005009373A3 (en) Tyrosine kinase inhibitors
EP0729957A4 (en) Pyridine compound and medicinal use thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed